Business
Oculis to Participate in Jefferies Healthcare Conference
ZUG, Switzerland and BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland and BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will attend the 2023 Jefferies Global Healthcare Conference in New York, from Wednesday, June 7 to Friday, June 9 for 1:1 meetings and will deliver a corporate presentation, on Friday, June 9, 2023 at 11:00-11:25 AM Eastern Time in Track 8. The archive replay of the presentation will be made available, following the event, in the Events & Presentations section of the “Investors and Media” section of the Oculis website at www.oculis.com, for at least 30 days thereafter. About Oculis Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors. For more information, please visit: www.oculis.com Contacts Investor Relations LifeSci AdvisorsCorey Davis, [email protected]+1-212-915-2577 Media Relations Consilium Strategic CommunicationsAmber Fennell, Tracy Cheung, David Daley [email protected] Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements and information. For example, statements r...